Syndax Pharmaceuticals Inc financial data

Symbol
SNDX on Nasdaq
Location
730 Third Avenue, 9 Th Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 520 % -42.1%
Quick Ratio 11.2 %
Debt-to-equity 224 % +1852%
Return On Equity -161 % -150%
Return On Assets -49.6 % +14.1%
Operating Margin -275 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 86.9M shares
Common Stock, Shares, Outstanding 86.9M shares +1.56%
Entity Public Float 1.7B USD
Common Stock, Value, Issued 9K USD 0%
Weighted Average Number of Shares Outstanding, Basic 86.6M shares +1.39%
Weighted Average Number of Shares Outstanding, Diluted 86.6M shares +1.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 112M USD +267%
Research and Development Expense 246M USD +6.24%
General and Administrative Expense 44.9M USD +44.4%
Operating Income (Loss) -307M USD +4.46%
Nonoperating Income (Expense) -4.68M USD -119%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -312M USD -4.89%
Earnings Per Share, Basic -3 USD/shares +1.37%
Earnings Per Share, Diluted -3 USD/shares +1.37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 117M USD -12.2%
Accounts Receivable, after Allowance for Credit Loss, Current 7.6M USD
Inventory, Net 25M USD
Other Assets, Current 3.51M USD
Assets, Current 530M USD +27.7%
Property, Plant and Equipment, Net 128K USD
Operating Lease, Right-of-Use Asset 1.47M USD +94.6%
Other Assets, Noncurrent 0 USD -100%
Assets 552M USD +29.6%
Accounts Payable, Current 13.8M USD +182%
Employee-related Liabilities, Current 15.6M USD +34.8%
Liabilities, Current 114M USD +92.3%
Operating Lease, Liability, Noncurrent 1.58M USD +173%
Liabilities 436M USD +635%
Retained Earnings (Accumulated Deficit) -1.44B USD -27.6%
Stockholders' Equity Attributable to Parent 115M USD -68.5%
Liabilities and Equity 552M USD +29.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -95.2M USD -13.9%
Net Cash Provided by (Used in) Financing Activities 930K USD -57.1%
Net Cash Provided by (Used in) Investing Activities 94.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 86.9M shares +1.56%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -90K USD +100%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 259M USD +25.6%
Deferred Tax Assets, Gross 259M USD +25.6%
Operating Lease, Liability 2.05M USD +27%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -319M USD -53%
Lessee, Operating Lease, Liability, to be Paid 2.45M USD +35.8%
Property, Plant and Equipment, Gross 419K USD 0%
Operating Lease, Liability, Current 329K USD -60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 656K USD +8.25%
Lessee, Operating Lease, Liability, to be Paid, Year One 657K USD -45.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 399K USD +111%
Lessee, Operating Lease, Liability, to be Paid, Year Three 675K USD
Deferred Tax Assets, Operating Loss Carryforwards 43.4M USD +32.8%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 143K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 48.5M USD +24.3%
Interest Expense 233K USD -87.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%